In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nexia Biotechnologies Inc.

Division of Altimmune Inc.

Latest From Nexia Biotechnologies Inc.

Satisfying the VC's Ultimate Customer

The current spate of biotech IPOs, and their relatively poor after-market performance, is unlikely to change VC investment practice more than it's changed already--but in recent times it's already changed profoundly. VCs are worried about going back to their ultimate customers--the limited partners--with the kinds of returns they've been able to generate so far.
BioPharmaceutical Medical Device

Canadian Biotech IPOs in 2000

Start-Up compares average amounts raised and valuations of biotech IPOs on NASDAQ versus those on Canadian exchanges.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Altimmune Inc.
  • Senior Management
  • Jeffrey D Turner, PhD, Pres. & CEO
    Dana L Rath, VP, Fin. & Admin.
    Costas N Karatzas, PhD, VP, R&D
    Edward Wein, PhD, VP, Bus. Dev.
  • Contact Info
  • Nexia Biotechnologies Inc.
    Phone: (514) 457-4522
    21025 Trans-Canada Hwy.
    St. Anne de Bellevue, H9X 3R2